Invene, a McKinney-based healthcare-focused engineering and AI solutions company, has acquired Austin-based Guidea, an award-winning product design consultancy with a two-decade track record serving Fortune 100 healthcare, medical device, and life sciences companies.

Invene, which was founded in 2018, said the strategic acquisition expands its capabilities beyond software engineering, positioning it as a “full-stack innovation partner, supporting the next generation of AI-driven healthcare products from blueprint to build.”

Terms of the acquisition were not disclosed.

“AI in healthcare can’t just be powerful—it has to be usable, compliant, and commercially viable,” Invene Founder and CEO James Griffin said in a statement. “Guidea brings the upstream clarity and clinical insight that helps us de-risk what gets built. Together, we’re helping mid-market and enterprise teams turn bold ideas into working AI products with measurable impact.”

Founded by Theresa Neil, Guidea has shaped the product strategy and design behind “some of the most innovative advancements in healthcare,” Invene said, including digital therapeutics, personalized medicine, AI-powered decision support, remote patient monitoring, and digital twins.

“The next phase of healthcare innovation will be shaped by AI, and success will depend on clear product strategy, strong clinical and market validation, and experienced execution,” said Neil, who joins Invene as chief product officer. “By combining deep domain expertise with engineering excellence in R&D, we can build AI solutions that actually work in practice.”

With Guidea’s design and strategy expertise, Invene says it’s now positioned to accelerate the delivery of clinically impactful, AI-enabled solutions across the healthcare ecosystem—”with greater usability, market relevance, and commercial success.”

The Guidea integration positions Invene to advance its evolution from an engineering services provider to a strategic partner for healthcare and life sciences enterprises navigating the complexity of AI, compliance, and clinical adoption.

The combined team offers end-to-end capabilities, including R&D strategy, clinical-grade UX design, AI implementation, and product commercialization, tailored to regulated healthcare environments.

Invene said the acquisition also enhances its ability to serve biopharma, diagnostics, and digital health clients seeking integrated support for clinical-grade innovation.

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.